New obesity drug tested in chinese adults: first safety results
NCT ID NCT06352892
First seen Jan 09, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This early-stage study tested a single injection of a new drug called AMG 133 (Maridebart Cafraglutide) in 20 Chinese adults who are overweight or have obesity. The main goal was to see how the drug moves through the body and to check for any safety issues. Participants were healthy aside from their weight, and the study is already completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Queen Mary Hospital
Hong Kong, 000, Hong Kong
Conditions
Explore the condition pages connected to this study.